Skye Bioscience, Inc. Common Stock (SKYE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.77 (+12.74%), Market cap $0.03B, 52-week low–high $0.58 ~ $4.75.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Financial statements, price targets, institutional (13F) holdings and related news for Skye Bioscience, Inc. Common Stock are updated in real time on BlackAll Trade.
Skye Bioscience, Inc. Common Stock trades at $1.77 (+12.74%). Real-time quotes and charts are available on BlackAll Trade.
Skye Bioscience, Inc. Common Stock has a market cap of about $0.03B.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. I